Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsAll Articles by Author:
Emily Salmini
Newsletters
Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
[Cancer Research] Scientists reported that abnormal accumulation of malonyl-CoA promotes lipogenesis and regulates metabolic processes, maintaining endoplasmic reticulum homeostasis and mitochondrial function and ultimately contributing to prostate cancer progression.
Newsletters
Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape, and Future Directions
[Current Oncology Reports] Emerging radioligands, novel combination therapies, optimized patient selection, and dose-personalization promise to improve outcomes and expand the use of radioligand therapies in prostate cancer.
Newsletters
Randomized Phase II Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT
[Journal of Nuclear Medicine] Researchers investigated the two year survival rate of patients with metastatic CRPC treated with an extended and flexible dosing schedule of [177Lu]Lu-PSMA-617 therapy in comparison to patients treated with the standard fixed dosing schedule of a maximum of six treatment cycles once every six weeks.
Newsletters
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
[Cancer Research Communications] Using an unbiased, combinatorial, high-throughput drug screen, researchers identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across androgen receptor-V7–expressing CRPC models.
Newsletters
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer
[Foresee Pharmaceuticals (PR Newswire)] Foresee Pharmaceuticals announced that the US FDA has approved the New Drug Application for CAMCEVI ETM as a treatment for advanced prostate cancer.
Intestinal Cell News
Takeda’s FRUZAQLATM (Fruquintinib) Publicly Reimbursed in Quebec for the Treatment of Metastatic Colorectal Cancer (mCRC)
[Takeda Canada, Inc. ] Takeda Canada, Inc. is pleased to announce that FRUZAQLATM will now be reimbursed by Régie de l’assurance maladie for people in Quebec, under certain criteria, as a treatment for adult patients with mCRCwho have been previously treated with, or are not considered candidates, for available standard therapies.
Popular
Aberrant PJA2-CHRM3 Signaling Creates a Therapeutic Vulnerability in Gastric Tumor
[British Journal of Cancer] Scientists constructed mouse gastric organoids to recapitulate the morphological and functional characteristics of diffuse-type gastric cancer for FDA-approved drug screening.
Damon Runyon Cancer Research Foundation Awards $4.8 Million to Exceptional Early-Career Scientists
[Damon Runyon Cancer Research Foundation] The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows. This fellowship encourages young scientists to pursue careers in cancer research by providing them with independent funding to investigate cancer causes, mechanisms, therapies, and prevention.
Tumor Transcriptome-Wide Expression Classifiers Predict Treatment Sensitivity in Advanced Prostate Cancers
[Cell] To identify novel biomarker-treatment pairings, researchers examined associations between biological pathways and 14-year survival outcomes of patients randomized in practice-changing Phase III trials. They included transcriptome-wide expression signatures and immunohistochemistry markers on prostate tumors from 1,523 patients.
